http://www.twitter.comTwitter is a service for friends, family, and co-workers to communicate and stay connected through the exchange of quick, frequent answers to one simple question: What are you doing?
View Older Stories
-
Anavex Life Sciences Provides Comprehensive Regulatory Update
-
Anavex withdraws EU marketing application for alzheimer's drug
-
Anavex Life Sciences Provides Update on Regulatory Review in the EU for Blarcamesine to Treat Early Alzheimer’s Disease
-
Anavex Life Sciences Presents New Data from its AD-004 Phase IIb/III Trial at AD/PD 2026 Conference Demonstrating Consistent Correlation Between the Treatment Effect of Oral Blarcamesine and Preservat
-
Anavex cites study supporting autophagy failure theory in Alzheimer's
-
New Scientific Findings Highlight Hypothesis of Autophagy Failure as a Precursor of Amyloid Beta and Tau Pathology in Alzheimer’s Disease
-
Anavex Life Sciences reports blarcamesine study results in Parkinson's model
-
Anavex Life Sciences Presents Significant Treatment Effects of Blarcamesine in New Advanced Alpha-Synuclein Model of Parkinson’s Disease at AD/PD 2026 Conference
-
Anavex Life Sciences to Present at the Citizens Life Sciences Conference
-
Anavex Life Sciences to Present at the 46th TD Cowen Annual Health Care Conference
-
Anavex Life Sciences adds AMEOS Group CEO to board of directors
-
Anavex Life Sciences Appoints Seasoned Healthcare Leader to Board of Directors
-
Anavex Life Sciences Reports Fiscal 2026 First Quarter Financial Results and Provides Business Update
-
Anavex Life Sciences to Announce Fiscal 2026 First Quarter Financial Results on Monday, February 9, 2026
-
Anavex Joins ACCESS-AD, a Major Initiative Funded by the European Commission, Through the Clinical Evaluation of Blarcamesine as Part of a Precision Medicine Approach in Alzheimer’s Disease
-
Anavex Life Sciences names Wolfgang Liedtke neurology head
-
Anavex Life Sciences Appoints Senior Vice President Global Head of Neurology
-
Anavex receives FDA feedback on Alzheimer's disease drug program
-
Anavex Life Sciences Receives FDA Feedback on Alzheimer’s Disease Program
-
Anavex requests EMA to re-examine blarcamesine for Alzheimer's
-
Anavex Life Sciences Submitted Request for EMA to Re-Examine Its Opinion
-
Anavex Life Sciences Provides Update on Regulatory Review in the EU for Blarcamesine to Treat Early Alzheimer’s Disease
-
Anavex Life Sciences to Present Oral Blarcamesine Data at the 18th Clinical Trials on Alzheimer’s Disease (CTAD) Conference
-
Anavex Life Sciences Reports Fiscal 2025 Fourth Quarter Financial Results and Provides Business Update
-
Anavex Life Sciences to Present at the 44TH ANNUAL J.P. MORGAN Healthcare Conference
-
Anavex Life Sciences to Announce Fiscal 2025 Fourth Quarter Financial Results on Tuesday, November 25, 2025
-
Anavex receives negative vote from European regulators on Alzheimer drug
-
Anavex Life Sciences Provides Regulatory Update on Blarcamesine for Early Alzheimer's Disease
-
Anavex Life Sciences Provides Regulatory Update on Blarcamesine for Early Alzheimer's Disease
-
Anavex reports long-term cognitive benefits from blarcamesine in alzheimer's trial
-
Anavex Life Sciences Announces Continued Long-Term Benefit from Oral Blarcamesine Compared to Decline Observed in the Alzheimer’s Disease Neuroimaging Initiative (ADNI) Control Group
-
ANAVEX presents Alzheimer's drug research at European conference
-
Anavex Life Sciences Announces Presentation at the 35th Alzheimer Europe Conference ‘Connecting Science and Communities: The Future of Dementia Care’
-
Anavex Life Sciences develops once-daily tablet for ANAVEX3-71 drug
-
Anavex Life Sciences Announces Successful Development of Once-Daily Oral Tablet Formulation for the ANAVEX®3-71 Program
-
Anavex reports positive phase 2 schizophrenia study results
-
Anavex Life Sciences Announces Positive Topline Results from Phase 2 Study of ANAVEX®3-71 for the Treatment of Schizophrenia
-
Anavex Life Sciences Announces Publication of Oral Blarcamesine Describing a New Class of Clinical Precision Medicine from Phase IIb/III Alzheimer’s Disease Trial
-
Anavex Life Sciences Announces Oral Blarcamesine Cognitive Resilience Results Approximating Normal Aging in New Precision Medicine Clinical Data from Phase IIb/III Alzheimer’s Disease Trial
-
Anavex Life Sciences to Present at the H.C. Wainwright 27th Annual Global Investment Conference 2025
-
ANAVEX publishes research on blarcamesine autophagy mechanism
-
Anavex Life Sciences Reports New Publication in Medical Journal Highlighting the Established Precise Autophagy Mechanism with Blarcamesine
-
Anavex reports study showing blarcamesine prevented memory loss in mice
-
Anavex Life Sciences Announces New Publication in Medical Journal: Blarcamesine Prevented Cognitive Impairment in Animal Model of Alzheimer’s Disease
-
Anavex Life Sciences Reports Fiscal 2025 Third Quarter Financial Results and Provides Business Update
-
Anavex Life Sciences to Announce Fiscal 2025 Third Quarter Financial Results on Tuesday, August 12, 2025
-
Anavex reports blarcamesine shows cognitive benefits in alzheimer's trial
-
Anavex Life Sciences Announces Positive Precision Medicine Results from up to 4-Years of Oral Blarcamesine Treatment in Phase IIb/III Open-Label Extension Trial in Early Alzheimer’s Disease
-
Anavex Life Sciences to Participate at Upcoming Healthcare Conferences
-
Anavex Life Sciences Reports Fiscal 2025 Second Quarter Financial Results and Provides Business Update
